Drug Profile


Alternative Names: DDATHF; LY 264618; T 904064; T-64

Latest Information Update: 02 Dec 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dana-Farber Cancer Institute
  • Class 2 ring heterocyclic compounds; Amides; Glutamates; Pyrimidines
  • Mechanism of Action DNA synthesis inhibitors; Phosphoribosylglycinamide formyltransferase inhibitors; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer; Cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Sarcoma; Solid tumours

Most Recent Events

  • 31 Jan 2003 Tularik has terminated its licensing agreement for T 64
  • 19 Jun 2002 Discontinued - Phase-II for Breast cancer in Australia (IV)
  • 19 Jun 2002 Discontinued - Phase-II for Breast cancer in Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top